This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| ACOD/CGSP | |
|---|---|
| Name | ACOD/CGSP |
| Synonyms | ACOD; CGSP |
| Routes of administration | Oral; Intravenous |
| Legal status | Prescription-only |
ACOD/CGSP ACOD/CGSP is a pharmacological agent developed for thromboinflammatory and thromboembolic indications, emerging from collaborations among academic centers, biotechnology firms, and regulatory agencies. It has been evaluated in multicenter trials, translational research programs, and postmarketing surveillance coordinated by institutions and consortia across North America, Europe, and Asia.
ACOD/CGSP was developed amid translational efforts linking discoveries from Harvard Medical School, Massachusetts Institute of Technology, Stanford University School of Medicine, University of Oxford, and industry partners such as Pfizer, AstraZeneca, Roche, Bayer AG, and Johnson & Johnson. Early studies referenced work from laboratories at Johns Hopkins University, Karolinska Institutet, Max Planck Society, Imperial College London, University of California, San Francisco, and Yale University. Development programs received funding and collaboration from foundations including the Wellcome Trust, the Bill & Melinda Gates Foundation, and the National Institutes of Health.
Preclinical discovery drew on biochemical research traditions exemplified by teams at Cold Spring Harbor Laboratory, Salk Institute, and The Francis Crick Institute. Initial candidate optimization involved medicinal chemistry groups formerly associated with GlaxoSmithKline and Novartis. Phase I and II trials were run at clinical trial networks including ClinicalTrials.gov-listed sites, cooperative groups such as the European Medicines Agency trial networks, and university hospitals including Mayo Clinic, Cleveland Clinic, and Karolinska University Hospital. Pivotal randomized controlled trials compared ACOD/CGSP to comparators used in guidelines from American Heart Association, European Society of Cardiology, and National Institute for Health and Care Excellence.
ACOD/CGSP's molecular design integrated structure–activity relationships characterized by techniques from X-ray crystallography, cryo-electron microscopy, and computational platforms developed at Google DeepMind and IBM Research. Lead optimization used high-throughput screening platforms pioneered at Broad Institute, cheminformatics pipelines from European Bioinformatics Institute, and formulation technologies from Takeda Pharmaceuticals. Device-associated delivery systems involved collaborations with medical device groups at Medtronic and Stryker Corporation for catheters and infusion pumps.
Clinical development targeted indications supported by guideline panels from American College of Cardiology, World Health Organization, Society for Thrombosis and Haemostasis Research, and specialty societies such as International Society on Thrombosis and Haemostasis and European Respiratory Society. Indications assessed included prevention and treatment endpoints endorsed in trials designed by investigators affiliated with Mount Sinai Health System, Duke University School of Medicine, Stanford Health Care, UCSF Health, and consortiums including Translational Research in Europe. Comparative effectiveness studies referenced treatments from Warfarin, dabigatran, rivaroxaban, apixaban, and interventional approaches evaluated at centers like Mayo Clinic and Cleveland Clinic.
Pharmacodynamic and pharmacokinetic characterization employed assays and models developed at National Institutes of Health, European Molecular Biology Laboratory, and Roche Diagnostics. Mechanistic hypotheses were informed by signaling pathways studied at Scripps Research, Friedrich Miescher Institute, and Weizmann Institute of Science. Mode-of-action studies cited interactions relevant to targets investigated by researchers at Columbia University Irving Medical Center, University of Toronto, Seoul National University, and Monash University.
Safety evaluations were overseen by data monitoring committees with membership drawn from Food and Drug Administration, European Medicines Agency, Health Canada, and independent academicians from Johns Hopkins University, University College London, and Karolinska Institutet. Reported adverse events were catalogued using standards maintained by World Health Organization pharmacovigilance programs and postmarketing surveillance coordinated with national pharmacovigilance centers such as Yellow Card Scheme partners and databases indexed in VigiBase. Contraindications and risk mitigation strategies referenced guidelines from American College of Chest Physicians, National Health Service (England), and professional societies including European Society of Cardiology.
Regulatory submissions incorporated data formatted per standards from International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, with reviews by Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, and Pharmaceuticals and Medical Devices Agency (Japan). Post-approval access strategies involved health technology assessment bodies such as National Institute for Health and Care Excellence, Institute for Clinical and Economic Review, and national reimbursement agencies across Germany, France, Canada, and Australia.
Category:Pharmaceuticals